Medicine and Dentistry
Immunotherapy
100%
Hepatocellular Carcinoma
100%
Sorafenib
37%
Immunity
37%
Overall Survival
25%
Immune Checkpoint Inhibitor
25%
Atezolizumab
25%
Cabozantinib
25%
Malignant Neoplasm
12%
Disease
12%
Biological Marker
12%
Monotherapy
12%
Progression Free Survival
12%
Immune Response
12%
Nivolumab
12%
Immune-Related Adverse Events
12%
Systemic Therapy
12%
Liver Cancer
12%
Ipilimumab
12%
Pembrolizumab
12%
Clinical Decision Making
12%
Lenvatinib
12%
Ramucirumab
12%
Immune Evasion
12%
Regorafenib
12%
Durvalumab
12%
Ticilimumab
12%
Genomic Signature
12%
Bevacizumab
12%
Keyphrases
Hepatocellular Carcinoma
100%
Sorafenib
37%
Overall Survival
25%
Etiology
25%
Immune Checkpoint Inhibitors
25%
Immune Microenvironment
25%
Atezolizumab
25%
Cabozantinib
25%
Immune Response
12%
Cancer Causes
12%
Cancer Mortality
12%
Liver Cancer
12%
Immune Evasion
12%
FDA-approved Drugs
12%
Monotherapy
12%
Progression-free Survival
12%
Response Mechanism
12%
Immune-related Adverse Events
12%
Phase II Trial
12%
Efficacy Data
12%
Immune Parameters
12%
Genomic Signature
12%
Clinical Decision-making
12%
Non-inflamed
12%
Pembrolizumab
12%
Systemic Therapy
12%
Bevacizumab
12%
Early Efficacy
12%
Regorafenib
12%
Accelerated Approval
12%
Lenvatinib
12%
Durvalumab
12%
Ramucirumab
12%
Settings-based
12%
Nivolumab Plus Ipilimumab
12%
Tremelimumab
12%
Immunology and Microbiology
Immunotherapy
100%
Immunity
100%
Sorafenib
50%
Overall Survival
33%
Atezolizumab
33%
Cabozantinib
33%
Immune Response
16%
Immune Evasion
16%
Progression Free Survival
16%
Ipilimumab
16%
Nivolumab
16%
Tremelimumab
16%
Durvalumab
16%
Lenvatinib
16%
Clinical Decision Making
16%
Ramucirumab
16%
Bevacizumab
16%
Regorafenib
16%
Pembrolizumab
16%
Pharmacology, Toxicology and Pharmaceutical Science
Immunotherapy
100%
Liver Cell Carcinoma
100%
Sorafenib
37%
Overall Survival
25%
Immune Checkpoint Inhibitor
25%
Cabozantinib
25%
Atezolizumab
25%
Disease
12%
Adverse Event
12%
Biological Marker
12%
Malignant Neoplasm
12%
Monotherapy
12%
Progression Free Survival
12%
Liver Cancer
12%
Nivolumab
12%
Ipilimumab
12%
Pembrolizumab
12%
Lenvatinib
12%
Ramucirumab
12%
Durvalumab
12%
Regorafenib
12%
Tremelimumab
12%
Bevacizumab
12%